Kevin Danahy Appointed Chief Commercial Officer at Pulse Biosciences

Pulse Biosciences Inc. has appointed Kevin Danahy to the newly created role of chief commercial officer.

Danahy has more than 20 years of senior management experience building and managing strategic commercial organizations for medical technology companies. Most recently, he was president of Solmetex, driving revenue growth for the company by implementing scalable solutions, while overseeing strategy, sales, marketing, operations, engineering, and service efforts. Previously, at Zimmer Biomet, Danahy held roles of increasing responsibility, most recently as vice president of Global Emerging Technologies and Specialty Sales. Before his time at Zimmer Biomet, was senior director at Intuitive Surgical, where he successfully transformed the sales leadership training program. Early in his career, he served in commercial leadership roles at both Medtronic plc and Johnson & Johnson.

Danahy earned a master’s degree in science from Tufts University.
 
“As an industry veteran, Kevin has a proven track record of building exceptional commercial teams and implementing strategies to drive market penetration and significant growth with new medical technologies across a variety of medical disciplines,” said Darrin Uecker, president and CEO of Pulse Biosciences. “His broad experience selling complex novel platform technologies makes Kevin uniquely qualified to take on the chief commercial officer role at Pulse Biosciences as we grow the CellFX System business in dermatology and expand into new applications and markets. We are delighted to welcome Kevin to the Pulse Biosciences team and look forward to the impact he will have on expanding the commercial footprint for the CellFX System.”

In connection with his appointment, Danahy has been granted stock options to purchase an aggregate of 300,000 shares of company common stock. The stock options will be subject to a mix of time-based and performance-based vesting criteria over four years, subject to Danahy’s continued employment with Pulse Biosciences.
  
“It is a privilege to take on the role of CCO at such a transformational time for Pulse Biosciences. This team has done an incredible job developing a novel technology platform at the intersection of healthcare and technology that can address the needs of a broad patient population,” said Danahy. “I believe Pulse Bioscience’s proprietary NPS technology delivered by the CellFX System has the power to improve the lives of patients across aesthetics, dermatology and other medical specialties, and I’m excited to be a part of the next phase in the Company’s growth.” 
 
Pulse Biosciences is a bioelectric medicine company that developed Nano-Pulse Stimulation technology, which delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model.